Frontiers in Clinical Drug Research - Hematology is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of hematological disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of anemias, coagulopathies, vascular diseases and hematological malignancies.
Reviews in this series also include research on specific antibody targets, therapeutic methods, genetic hemoglobinopathies and pre-clinical/clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research - Hematology is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of hematology, oncology and vascular pharmacology.
The fourth volume of this series features 5 reviews:
Reviews in this series also include research on specific antibody targets, therapeutic methods, genetic hemoglobinopathies and pre-clinical/clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research - Hematology is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of hematology, oncology and vascular pharmacology.
The fourth volume of this series features 5 reviews:
- TRP Channels: Potential Therapeutic Targets in Blood Disorders
- Hypercoagulable States: Clinical Symptoms, Laboratory Markers and Management
- Advanced Applications of Gene Therapy in the Treatment of Hematologic Disorders
- Ferroptosis - Importance and Potential Effects in Hematological Malignancies
- Clinical Application of Liquid Biopsy in Solid Tumor HCC: Prognostic, Diagnostic and Therapy Monitoring Tool
Table of Contents
PrefaceList of Contributors
Chapter 1 Trp Channels: Potential Therapeutic Targets in Blood
- Disorders
- Introduction
- Trp Channels in Blood Disorders
- Trp Channels and Abnormalities in Rbcs
- Sickle Cell Disease (Scd)
- Trp Channels in Platelets Related Disorders
- Trpml and Iron-Deficiency Anaemia
- Trpm6 in Dysregulated Blood and Serum Mg2+ Homeostasis
- Trp Channels and Hematological Malignancies
- Trpm Channels
- Trpm1
- Trpm2
- Trpm4
- Trpm5
- Trpm7
- Trpm8
- Trpv Channels
- Trpv1
- Leukemia Cell Lines
- Adult T-Cell Leukemia (Atl)
- Multiple Myeloma (Mm)
- Trpv2
- Trpv5 and Trpv6
- Trpc Channels
- Trpc1
- Trpc2, Trpc3 and Trpc6
- Trpc7
- Trpp Channels
- Conclusions and Future Direction
- Abbreviations
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 2 Hypercoagulable States: Clinical Symptoms, Laboratory
- Markers and Management
- Introduction
- Clinical Symptoms
- Venous Thromboembolism (Vte)
- Pathophysiology
- Clinical Presentation
- Evaluation
- Arterial Thromboembolism
- Recurrent Venous Thromboembolism
- Risk Factors of Recurrent Vte
- Risk Factors/Predisposing Factors
- Management
- Hypercoagulable Disorders
- Antiphospholipid Syndrome
- Lupus Anticoagulant Testing
- Anticardiolipin and Β2Gpi Antibody Testing
- Management
- Venous Thrombotic Events
- Direct Oral Anticoagulants (Doacs)
- Non-Anticoagulant Treatment of Thrombotic Aps
- Factor V Leiden Mutation and Activated Protein C Resistance
- Factor V Leiden (Fvl)
- Management
- Prothrombin Gene G20210A Mutations
- Management
- Protein C Deficiency
- Pathophysiology
- Management
- Protein S Deficiency
- Pathophysiology
- Epidemiology
- Laboratory Tests
- Management
- Antithrombin Deficiency
- Laboratory Tests
- Hyperhomocysteinemia
- Management
- Elevated Factor Viii
- Dysfibrinogenemia
- Algorithmic Approach to Laboratory Testing
- Patient Selection
- Reason to Test
- The “4P” Approach
- Whom to Test
- Whom Not to Test
- Points to Consider in Requests for Laboratory Examinations
- Management
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 3 Advanced Applications of Gene Therapy in the Treatment of Haematologic Disorders
- Introduction
- Gene Therapy Techniques Used in the Treatment of Blood
- Disorders
- Gene Delivery Viral Vectors
- Haemophilia
- Β-Haemoglobinopathies
- Genome Editing Technology (Crispr-Cas9)
- How Does Crispr Work in Bacteria?
- Application of Crispr-Cas9 in Β-Haemoglobinopathies and Fanconi Anaemia
- Chimeric Antigen Receptor (Car) T-Cell Therapy
- Car T-Cell Therapy for Haematological Malignancies
- Car Modified-Hematopoietic Stem Cells
- Current Challenges and Future Outlook
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 4 Ferroptosis - Importance and Potential Effects in Hematological Malignancies
- Introduction
- Main Features of Different Programmed Cell Death Processes
- Introduction
- Apoptosis
- Autophagy
- Necroptosis
- Pyroptosis
- Ferroptosis
- Cellular Signaling Pathways
- Lipid Metabolism
- Amino Acid Metabolism
- Cystine Pathway
- Transsulfuration Pathway
- Mevalonate Pathway
- Nicotinamide Adenine Dinucleotide Phosphate Pathway
- Iron Metabolism
- Mapk Pathway
- Ros Metabolism
- Ros Production Pathways
- Ros Sources
- Control of Ferroptosis: Sensitivity Modulation
- Inducers
- Erastin
- Sulfasalazine
- Sorafenib
- Rsl3 and Rsl5
- Buthioninesulfoximine
- Acetaminophen
- Lanperisone
- Artesunate
- Glutamate
- Ml-162
- Diphenyleneiodonium Compounds
- Cystine/Cysteine Deprivation
- Cisplatin
- Fin56
- Fino2
- Statins
- Cysteinase
- Silica-Based Nanoparticles
- Ferric Ammonium Citrate
- Trigonelline
- Brusatol
- Inhibitors
- Vitamin E
- Ferrostatin
- Liproxstatin-1
- Zileuton
- Deuterated Polyunsaturated Fatty Acids
- Synthetic Antioxidants
- Coenzyme Q10
- Deferoxamine
- Glutaminolysis Inhibition
- Cycloheximide
- Beta-Mercaptoethanol
- Dopamine
- Selenium
- Inhibitors of Dipeptidyl Peptidase 4
- Dual Compounds
- Histone Deacetylase Inhibitors
- Positive Regulators
- P53
- Ras
- Tfr1
- Vdac2/3
- Cars
- Nox
- Microrna
- Negative Regulators
- Nrf2
- Gpx4
- System Xc-
- Microrna
- Hspb1
- Ferroptosis and Cancer
- Diffuse Large B-Cell Lymphoma
- T-Cell Lymphoma
- Leukaemia
- Multiple Myeloma
- Hepatocellular Carcinoma
- Colorectal Cancer
- Gastric Cancer
- Prostate Adenocarcinoma
- Ovarian Cancer
- Breast Cancer
- Pancreatic Cancer
- Lung Carcinoma
- Renal Carcinoma
- Ferroptosis and Non-Malignancies Diseases
- Intracerebral Haemorrhage
- Cardiomyopathy
- Hepatopathy
- Acute Kidney Failure
- Conclusion
- Abbreviations
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 5 Clinical Application of Liquid Biopsy in Solid Tumor Hcc:
- Prognostic, Diagnostic and Therapy Monitoring Tool
- Introduction
- Presence of Tumor Derived Components in Plasma
- History and Biology of Liquid Biopsy
- Circulating Tumor Cells (Ctcs)
- Characteristics and Detection Techniques of Circulating Tumor
- Cells
- Enrichment Methods
- Magnetic Activated Cell Sorting (Macs)
- Density-Based Cell Separation
- Size-Based Cell Separation
- Magnetophoretic Mobility Based Cell Separation
- Dielectrophoretic (Dep) Ctcs Separation
- Affinity Chromatography Ctcs Separation
- Detection Techniques
- Direct Detection Using a Line-Confocal Microscope
- Detection of Ctcs by Sers Nanoparticles
- Fluorescence Assisted Cell Sorting (Facs)
- Nucleic-Acid-Based Detection
- Ctcs in Hcc Patients
- Circulating Tumor Dna (Ctdna)
- Characteristics and Detection Tools
- Real Time Pcr Based Methods
- Methylation-Specific Pcr
- Droplet Digital Pcr (Ddpcr)
- Beaming (Beads Emulsion, Amplification Magnetic)
- Next-Generation Sequencing (Ngs)
- Tagged-Amplicon Deep Sequencing (Tam-Seq)
- Cancer Personalized Profiling by Deep Sequencing (Cappseq)
- Safe-Sequencing System (Safe-Seqs)
- Ion Torrent
- Personalized Analysis of Rearrangement Ends (Pare)
Author
- Atta-ur-Rahman
